First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Eli Lilly and Company (NYSE:LLY) offers a quarterly dividend of $1.50 per share and has a dividend yield of 0.71%, as of March 20. It is one of the best dividend stocks on our list as the company has ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Ironically, as fashion embraces (and creates) faux womanly figures by design, the actual bodies inside the clothes are ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

One popular and affordable supplement that has shown some promise in helping with weight loss is berberine. In fact, some have called the supplement “nature’s Ozempic,” and with a month’s supply ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...